{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:29:25Z","timestamp":1793899765147,"version":"4.8.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA227576"],"award-info":[{"award-number":["R01CA227576"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Principal Investigator","award":["U24CA55727"],"award-info":[{"award-number":["U24CA55727"]}]},{"name":"Intramural Research Program of the National Institutes of Health)"},{"name":"The St. Jude Children\u2019s Research Hospital","id":[{"id":"https:\/\/ror.org\/02r3e0967","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Cancer Center Support","award":["CA21765"],"award-info":[{"award-number":["CA21765"]}]},{"name":"American Lebanese-Syrian Associated Charities"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pediatric advanced-stage Hodgkin lymphoma (HL) is highly curable, yet survivors treated with historical regimens face substantial late morbidity and excess mortality. Immunotherapy-based frontline therapies improve disease control, but late toxicities remain unknown. We developed a simulation model to project lifetime outcomes after contemporary brentuximab vedotin- or nivolumab-containing regimens using trial data (COG AHOD1331 and SWOG S1826), Childhood Cancer Survivor Study data, and national databases. We assessed how changes in frontline and relapse therapy could influence long-term survival and late-effect outcomes, using sensitivity analyses to evaluate potential immunotherapy-related late mortality. Compared with expected survival at age 50 in the general population, HL survival was 86% after historical regimens and 92%-93% after contemporary immunotherapy-based therapies. Survival gains persisted unless immunotherapy-related late mortality exceeded approximately 8%. These projections suggest contemporary regimens may narrow the long-term survival gap while reducing late-effect burden.<\/jats:p>","DOI":"10.1093\/jnci\/djag353","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:53:44Z","timestamp":1790855624000},"source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy-based therapies in pediatric Hodgkin lymphoma: potential to narrow the gap in long-term survival"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2975-2083","authenticated-orcid":false,"given":"Jenna R","family":"Rogers","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of General Pediatrics, Boston Children\u2019s Hospital , Boston, MA,","place":["United States"]},{"name":"Interfaculty Initiative in Health Policy, Harvard University , Cambridge, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary J","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Harvard T.H. Chan School of Public Health , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M","family":"Feraco","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center Department of Pediatric Oncology, , Boston, MA,","place":["United States"]},{"name":"Department of Pediatrics, Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M","family":"Castellino","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine , Atlanta, GA,","place":["United States"]},{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla L","family":"Stratton","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-0906","authenticated-orcid":false,"given":"Wendy M","family":"Leisenring","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory T","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Cancer Control, St. Jude Children\u2019s Research Hospital , Memphis, TN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7712-961X","authenticated-orcid":false,"given":"Eric J","family":"Chow","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca M","family":"Howell","sequence":"additional","affiliation":[{"name":"Department of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M","family":"Hudson","sequence":"additional","affiliation":[{"name":"Department of Oncology, St. Jude Children\u2019s Research Hospital , Memphis, TN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1473-3937","authenticated-orcid":false,"given":"Kara M","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences , Buffalo, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M","family":"Morton","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0806-7894","authenticated-orcid":false,"given":"Kevin C","family":"Oeffinger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University , Durham, NC,","place":["United States"]},{"name":"Duke Cancer Institute , Durham, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Diller","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center Department of Pediatric Oncology, , Boston, MA,","place":["United States"]},{"name":"Department of Pediatrics, Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2724-7404","authenticated-orcid":false,"given":"Jennifer M","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of General Pediatrics, Boston Children\u2019s Hospital , Boston, MA,","place":["United States"]},{"name":"Department of Pediatrics, Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026110512211525800_djag353-B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026110512211525800_djag353-B2","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/blood-2015-07-641035","article-title":"Hodgkin lymphoma in children and adolescents: improving the therapeutic index","volume":"126","author":"Kelly","year":"2015","journal-title":"Blood"},{"key":"2026110512211525800_djag353-B3","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1200\/JCO.20.01186","article-title":"Impact of risk-adapted therapy for pediatric Hodgkin lymphoma on risk of long-term morbidity: a report from the childhood cancer survivor study","volume":"39","author":"Oeffinger","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026110512211525800_djag353-B4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamaoncol.2025.0236","article-title":"Accelerated aging in survivors of childhood cancer-early onset and excess risk of chronic conditions","volume":"11","author":"Yeh","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026110512211525800_djag353-B5","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1056\/NEJMe2211587","article-title":"Are we too reliant on radiation therapy for children with Hodgkin\u2019s lymphoma?","volume":"387","author":"Roschewski","year":"2022","journal-title":"N Engl J Med"},{"key":"2026110512211525800_djag353-B6","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin\u2019s lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N Engl J Med"},{"key":"2026110512211525800_djag353-B7","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab\u2009+\u2009AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"2026110512211525800_djag353-B8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1200\/JCO-25-00203","article-title":"Three-year follow-up of nivolumab-AVD versus brentuximab vedotin-AVD in adolescents with advanced-stage classic Hodgkin lymphoma on S1826","volume":"44","author":"Castellino","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026110512211525800_djag353-B9","first-page":"2075","article-title":"Nivolumab and brentuximab vedotin with or without bendamustine for R\/R Hodgkin lymphoma in children, adolescents, and young adults","volume":"141","author":"Harker-Murray","year":"2023","journal-title":"Blood"},{"key":"2026110512211525800_djag353-B10","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.ijrobp.2025.06.3876","article-title":"Comparison of contemporary radiation therapy approaches in combined modality treatment on pediatric high-risk classic Hodgkin lymphoma study: AHOD 1331","volume":"123","author":"Hoppe","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026110512211525800_djag353-B11","doi-asserted-by":"publisher","first-page":"e2351062","DOI":"10.1001\/jamanetworkopen.2023.51062","article-title":"Late cardiac toxic effects associated with treatment protocols for Hodgkin lymphoma in children","volume":"7","author":"Lo","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026110512211525800_djag353-B12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.ijrobp.2026.01.026","article-title":"Subsequent neoplasm risk after modern mediastinal radiation therapy for pediatric Hodgkin lymphoma: insights from a multi-institutional children\u2019s oncology group trial","volume":"125","author":"Milgrom","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026110512211525800_djag353-B13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026110512211525800_djag353-B14","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1200\/JCO.2009.22.3339","article-title":"The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research","volume":"27","author":"Robison","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026110512211525800_djag353-B15","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1200\/JCO.2008.21.1813","article-title":"Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study","volume":"27","author":"Leisenring","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026110512211525800_djag353-B16","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/s41591-023-02514-1","article-title":"Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer","volume":"29","author":"Wang","year":"2023","journal-title":"Nat Med"},{"key":"2026110512211525800_djag353-B17","author":"Children\u2019s Oncology Group","year":"2023"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag353\/71559981\/djag353.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag353\/71559981\/djag353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:21:24Z","timestamp":1793899284000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article\/doi\/10.1093\/jnci\/djag353\/8859109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":17,"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag353","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"djag353"}}